A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)
for Niemann-Pick Diseases
Sites in Chicago +4 more locations
Sponsor: Sanofi
Sex: All·Age: Up to 2
Code: NCT06192576·Recruiting·Listed Jan 2024